China Universal Asset Management Co. Ltd. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1,110.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,604 shares of the biopharmaceutical company’s stock after purchasing an additional 12,480 shares […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price increased by Morgan Stanley from $205.00 to $210.00 in a research report released on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. JPMorgan Chase […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 4,930,000 shares, a decline of 8.5% from the February 28th total of 5,390,000 shares. Based on an average daily volume of 781,100 shares, the days-to-cover ratio is currently 6.3 days. […]
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) have been given an average rating of “Moderate Buy” by the twenty-two research firms that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average […]
Verition Fund Management LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,827 shares of the biopharmaceutical company’s stock, valued at approximately $966,000. A number of other hedge funds have also […]